Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya shows positive long-term data in Crohn’s disease studies
智通财经2026/10/13 01:55Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
According to reports from Zhitong Finance APP, long-term data from two Phase 3 clinical trials conducted by Johnson & Johnson (JNJ.US) show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved clinical remission rates as high as 94% over three years.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like

Jefferies upgrades SpaceX rating to Buy with a target price of $210
智通财经•2026/11/22 15:56

Dell and Supermicro reportedly raise AI server prices by up to 45%
智通财经•2026/11/22 13:51

Novo founder says AI will spark a gold rush for solo entrepreneurs
智通财经•2026/11/22 02:26

Crypto prices
MoreBitcoin
BTC
$60,692.34
+0.86%
Ethereum
ETH
$1,709.32
+1.74%
Tether USDt
USDT
$0.9982
+0.03%
BNB
BNB
$555.87
+1.55%
USDC
USDC
$0.9998
-0.01%
XRP
XRP
$0.9203
-0.76%
Solana
SOL
$69.94
-0.31%
TRON
TRX
$0.3050
+0.03%
Hyperliquid
HYPE
$62.04
+1.28%
Zcash
ZEC
$785.46
-0.10%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now